Effects of endogenous cannabinoid anandamide on cardiac Na+/Ca2+ exchanger

Cell Calcium

Volumn 55, Issue 5, 2014, Pages 231-237

  Kury, Lina T Al ^a   Yang, Keun Hang Susan ^c   Thayyullathil, Faisal T ^a   Rajesh, Mohanraj ^a   Ali, Ramez M ^a   Shuba, Yaroslav M ^b   Howarth, Frank Christopher ^a   Galadari, Sehamuddin ^a   Oz, Murat ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^c CHAPMAN UNIVERSITY   (United States)

Author keywords

Anandamide; Whole cell patch clamp technique

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; FATTY ACID AMIDASE; METHANANDAMIDE; PERTUSSIS TOXIN; SODIUM CALCIUM EXCHANGE PROTEIN; YELLOW FLUORESCENT PROTEIN; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; MALE; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; WISTAR RAT;

RATTUS;

ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CALCIUM CHANNEL BLOCKERS; CARBAMATES; CELLS, CULTURED; ENDOCANNABINOIDS; HEK293 CELLS; HUMANS; MALE; MICROSCOPY, CONFOCAL; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; SODIUM-CALCIUM EXCHANGER;

EID: 84899947849     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2014.02.017     Document Type: Article

References (49)

1. Di Marzo V., De Petrocellis L., Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb. Exp. Pharmacol. 2005, 168:147-185.
2. Hanus L.O., Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr. Med. Chem. 2010, 17:1341-1359.
3. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
4. Pertwee R.G., Howlett A.C., Abood M.E., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol. Rev. 2010, 62:588-631.
5. Bonz A., Laser M., Kullmer S., et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 2003, 41:657-664.
6. Batkai S., Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol. Res. 2009, 60:99-106.
7. Montecucco F., Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol. Sci. 2012, 33:331-340.
8. Ford W.R., Honan S.A., White R., Hiley C.R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol. 2002, 135:1191-1198.
9. Wagner J.A., Jarai Z., Batkai S., Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur. J. Pharmacol. 2001, 423:203-210.
10. Krylatov A.V., Uzhachenko R.V., Maslov L.N., et al. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull. Exp. Biol. Med. 2002, 133:122-124.
11. Ugdyzhekova D.S., Bernatskaya N.A., Stefano J.B., Graier V.F., Tam S.W., Mekhoulam R. Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors. Bull. Exp. Biol. Med. 2001, 131:251-253.
12. Goldhaber J.I., Philipson K.D. Cardiac sodium-calcium exchange and efficient excitation-contraction coupling: implications for heart disease. Adv. Exp. Med. Biol. 2013, 961:355-364.
13. 2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure. Curr. Drug Targets 2011, 12:737-747.
14. 2+ in streptozotocin-induced diabetic rats. Pflugers Arch. 2002, 444:446-451.
15. 2+ exchanger current from guinea-pig isolated ventricular myocytes. Clin. Exp. Pharmacol. Physiol. 2002, 29:777-781.
16. Abadji V., Lin S., Taha G., et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 1994, 37:1889-1893.
17. Lan R., Liu Q., Fan P., et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42:769-776.
18. Ross R.A., Brockie H.C., Stevenson L.A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 1999, 126:665-672.
19. 2+ current by beta3-adrenergic stimulation in failing rat heart. J. Pharmacol. Exp. Ther. 2005, 315:1203-1211.
20. 2+ entry into endothelial cells and activates BKCa channels independently of GPCRs. Br. J. Pharmacol. 2013, 169:933-948.
21. Randall M.D., Kendall D.A., O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. 2004, 142:20-26.
22. Mendizabal V.E., Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br. J. Pharmacol. 2007, 151:427-440.
23. Malinowska B., Baranowska-Kuczko M., Schlicker E. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?. Br. J. Pharmacol. 2012, 165:2073-2088.
24. Oz M., Jaligam V., Galadari S., Petroianu G., Shuba Y.M., Shippenberg T.S. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J. Neurochem. 2010, 112:1454-1464.
25. Tsumura M., Sobhan U., Muramatsu T., et al. TRPV1-mediated calcium signal couples with cannabinoid receptors and sodium-calcium exchangers in rat odontoblasts. Cell Calcium 2012, 52:124-136.
26. Dvorakova M., Kummer W. Transient expression of vanilloid receptor subtype 1 in rat cardiomyocytes during development. Histochem. Cell Biol. 2001, 116:223-225.
27. 2+ exchanger current in rat cardiac myocytes. PLoS ONE 2013, 8.
28. 2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004, 321:116-123.
29. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipid. 2000, 108:135-150.
30. Berger C., Schmid P.C., Schabitz W.R., Wolf M., Schwab S., Schmid H.H. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?. J. Neurochem. 2004, 88:1159-1167.
31. Epps D.E., Schmid P.C., Natarajan V., Schmid H.H. N-Acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 1979, 90:628-633.
32. Epps D.E., Mandel F., Schwartz A. The alteration of rabbit skeletal sarcoplasmic reticulum function by N-acylethanolamine, a lipid associated with myocardial infarction. Cell Calcium 1982, 3:531-543.
33. Schmid H.H., Berdyshev E.V. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:363-376.
34. Meves H. Modulation of ion channels by arachidonic acid. Prog. Neurobiol. 1994, 43:175-186.
35. Voitychuk O.I., Asmolkova V.S., Gula N.M., et al. Modulation of excitability, membrane currents and survival of cardiac myocytes by N-acylethanolamines. Biochim. Biophys. Acta 2012, 1821:1167-1176.
36. +) fluxes in rabbit T-tubule membranes. Eur. J. Pharmacol. 2000, 404:13-20.
37. Oz M., Tchugunova Y., Dinc M. Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. Eur. J. Pharmacol. 2004, 502:47-58.
38. + fluxes in rabbit T-tubule membranes. Arch. Biochem. Biophys. 2005, 434:344-351.
39. Alptekin A., Galadari S., Shuba Y., Petroianu G., Oz M. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. Eur. J. Pharmacol. 2010, 634:10-15.
40. Li.Q., Ma H.J., Zhang H., Qi Z., Guan Y., Zhang Y. Electrophysiological effects of anandamide on rat myocardium. Br. J. Pharmacol. 2009, 158:2022-2029.
41. Gulaya N.M., Melnik A.A., Balkov D.I., Volkov G.L., Vysotskiy M.V., Vaskovsky V.E. The effect of long-chain N-acylethanolamines on some membrane-associated functions of neuroblastoma C1300 N18 cells. Biochim. Biophys. Acta 1993, 1152:280-288.
42. Mavromoustakos T., Papahatjis D., Laggner P. Differential membrane fluidization by active and inactive cannabinoid analogues. Biochim. Biophys. Acta 2001, 1512:183-190.
43. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol. Ther. 2006, 111:114-144.
44. McIntosh T.J., Simon S.A. Roles of bilayer material properties in function and distribution of membrane proteins. Annu. Rev. Biophys. Biomol. Struct. 2006, 35:177-198.
45. Andersen O.S., Koeppe R.E. Bilayer thickness and membrane protein function: an energetic perspective. Annu. Rev. Biophys. Biomol. Struct. 2007, 36:107-130.
46. Spivak C.E., Lupica C.R., Oz M. The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol. Pharmacol. 2007, 72:1024-1032.
47. + ATPase of cardiac sarcoplasmic reticulum: physiological role and relevance to diseases. Biochem. Biophys. Res. Commun. 2008, 369:182-187.
48. Eisner D., Bode E., Venetucci L., Trafford A. Calcium flux balance in the heart. Mol. Cell. Cardiol. 2013, 58:110-117.
49. Vafiadaki E., Arvanitis D.A., Pagakis S.N., Papalouka V., Sanoudou D., Kontrogianni-Konstantopoulos A., Kranias E.G. The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol. Biol. Cell 2009, 20:306-318.